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Abstract
Background: Neuroinflammatory processes are considered a double-edged sword, having both protective and
detrimental effects in the brain. Microglia, the brain’s resident innate immune cells, are a key component of
neuroinflammatory response. There is a growing interest in developing drugs to target microglia and control
neuroinflammatory processes. In this regard, docosahexaenoic acid (DHA), the brain’s n-3 polyunsaturated fatty acid, is
a promising molecule to regulate pro-inflammatory microglia and cytokine production. Several works reported that the
bioavailability of DHA to the brain is higher when DHA is acylated to phospholipid. In this work, we analyzed the anti-
inflammatory activity of DHA-phospholipid, either acetylated at the sn-1 position (AceDoPC, a stable form thought to
have superior access to the brain) or acylated with palmitic acid at the sn-1 position (PC-DHA) using a
lipopolysaccharide (LPS)-induced neuroinflammation model both in vitro and in vivo.
Methods: In vivo, adult C57Bl6/J mice were injected intravenously (i.v.) with either AceDoPC or PC-DHA 24 h prior to
LPS (i.p.). For in vitro studies, immortalized murine microglia cells BV-2 were co-incubated with DHA forms and LPS.
AceDoPC and PC-DHA effect on brain or BV-2 PUFA content was assessed by gas chromatography. LPS-induced
pro-inflammatory cytokines interleukin IL-1β, IL-6, and tumor necrosis factor (TNF) α production were measured by
quantitative PCR (qPCR) or multiplex. IL-6 receptors and associated signaling pathway STAT3 were assessed by FACS
analysis and western-blot in vitro.
Results: In vivo, a single injection of AceDoPC or PC-DHA decreased LPS-induced IL-6 production in the hippocampus
of mice. This effect could be linked to their direct effect on microglia, as revealed in vitro. In addition, AceDoPC or PC-
DHA reduced IL-6 receptor while only AceDoPC decreased IL-6-induced STAT3 phosphorylation.
Conclusions: These results highlight the potency of administered DHA—acetylated to phospholipids—to rapidly
regulate LPS-induced neuroinflammatory processes through their effect on microglia. In particular, both IL-6
production and signaling are targeted by AceDoPC in microglia.
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Background
Docosahexaenoic acid (DHA) is a prominent long chain
omega-3 polyunsaturated fatty acid (LC PUFA) of the
brain, where it regulates both the structure and function
of neurons, glia, and endothelial cells [1]. This PUFA
also exerts protective activity against inflammation in
the brain. Indeed, using a combination of dietary and
transgenic mice models, we and others have demon-
strated that increased brain DHA attenuates neuroin-
flammatory processes, while decreased brain DHA
promotes them [2–10]. DHA’s role in neuroinflammation
is likely due to its direct effect on microglia, the resident
innate immune cells of the brain, and its oxygenase-
derived metabolites (neuroprotectins, resolvins, maresins)
and endocannabinoid-like metabolites [2, 9, 11–18].
Brain DHA levels rely on dietary content [19]. DHA is
either synthesized from the essential PUFA alpha-
linolenic acid (ALA, 18:3 n-3) or consumed preformed
from marine sources [20, 21]. Despite the brain express-
ing the enzymes necessary to synthesize DHA from
ALA, the synthesis rate is much lower than the rate of
DHA uptake from the plasma, suggesting that the diet is
a primary source of DHA to the brain [22–24]. Once
ingested, DHA is rapidly redistributed within (1) plasma
lipoproteins, mainly in triacylglycerols (TG) or phospho-
lipids (PL) (which constitute the major destination for
DHA) and (2) the albumin fraction as non-esterified
DHA or lysophosphatidylcholine-esterified DHA (lyso
PC-DHA) in the blood [25–27].
Several works report that the bioavailability of DHA to
the brain is better when DHA is in its lysoPC form in the
blood [28–31]. However, how DHA enters the brain is still
a matter of debate as both unesterified and lysoPC-DHA
forms are good source of brain DHA [26, 32]. Several
reports are in favor of a preferential crossing of the blood-
brain barrier (BBB) when DHA is esterified at the sn-2
position of lysoPC-DHA [28, 31]. This is supported
by the recent discovery of MFSD2A (major facilitating
superfamily domain-containing protein 2A), an exclu-
sive transporter of lysoPC-DHA expressed by endo-
thelial cells of BBB [33]. Importantly, in regard to
brain diseases, DHA in the form of lysophospholipid
has a longer plasma half-life and, as a result, in-
creases DHA brain exposure [26].
In the lysoPC form, DHA is initially esterified at the
sn-2 position. However, it rapidly changes from the
physiological sn-2 position to the more stable but non-
physiological sn-1 position. Then, to prevent such a
migration, we acetylated the sn-1 position that results in
a structured phospholipid, 1-acetyl,2-docosahexaenoyl-
PC (AceDoPC) [34]. This structure mimics and behaves
like 2-DHA-lysoPC in terms of DHA accumulation in
the brain and has been shown to exert different bio-
logical properties such as the prevention of experimental
stroke or the inhibition of the platelet-activating factor-
induced aggregation in rats [34, 35].
Despite the possibility of a privileged entry of
AceDoPC in the brain [36], its potential effect on neu-
roinflammatory pathways has not been explored. In this
work, we investigated the effects of AceDoPC as com-
pared to PC-DHA(1-palmitoyl,2-docosahexaenoyl-PC),
previously shown to also increase delivery of DHA to
brain when acutely administered [4]. We tested this in
lipopolysaccharide (LPS)-induced neuroinflammation in
both in vitro and in vivo models and probed the under-
lying signaling mechanisms. We found that a single in
vivo administration of AceDoPC or PC-DHA specifically
reduced LPS-induced interleukin-6 (IL-6), a pro-
inflammatory cytokine, in the hippocampus but not in
the hypothalamus. In vitro, AceDoPC significantly
decreased microglia activation and IL-6-induced nuclear
translocation of STAT3 in microglia cells through the
downregulation of IL-6 receptor subunit gp130. AceDoPC
effect on microglia and neuroinflammatory pathways sug-




Animal husbandry and experimental procedures were in
accordance with the EU Directive 2010/63/EU for animal
experiments and approved by the national ethical commit-
tee for care and use of animals (approval ID A13169).
C57BL6/J mice from Janvier (Le Genest St Isle, France)
were received at 10 weeks of age, housed individually and
maintained in a temperature (22 ± 1 °C) and humidity con-
trolled facility on a 12 h light-dark cycle with free access to
food and water. They were fed a standard chow diet (A04,
Safe, Augy, France). Experiments were performed at
12 weeks of age. The day before the experiment,
plasma from C57BL/6 J (n = 10) was isolated as pre-
viously described [35]. Briefly, mouse blood was col-
lected in tubes containing heparin and centrifuged for
10 min at 2600 g. Plasma was collected and incubated
overnight at 4 °C with AceDoPC [34] or PC-DHA
[34] or vehicle. Then, the mice were injected intra-
venously in the caudal vein at the following concen-
trations: 3.23 μg/g of mouse for AceDoPC and
4.33 μg/g of mouse for PC-DHA. Doses of AceDoPC
and PC-DHA administrated are equivalent to 1.7 μg/
mouse or ≈ 66 μM/mouse of DHA/mouse. Twenty-
four hours after injection, mice were injected intra-
peritoneally with LPS (Escherichia coli 0127:B8,
500 μg/kg) or NaCl (n = 3–6 per group) [20, 37].
Mice were sacrificed 6 h later by decapitation after
isoflurane anesthesia. Hippocampus and hypothalamus
were quickly collected, frozen on dry ice and stored
at −80 °C until analysis. Blood samples were obtained
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by cardiac puncture and collected in tubes containing 10%
EDTA. After 10 min centrifugation (10,000 g, 4 °C),
plasma was collected and kept at −80 °C.
Cell culture and treatments
BV-2 cells, an immortalized murine microglial cell line,
were cultured as previously described [16] in RPMI
medium (Invitrogen, Carlsbad, CA, USA) supplemented
with 10% heat-inactivated fetal calf serum (Eurobio,
Courtaboeuf, France), streptomycin sulfate (50 μg/mL),
phenoxypenicillinic acid (65 μg/mL), and glutamine
(65 μg/mL) in 5% CO2 at 37 °C. Cells were seeded at a
density of 500,000 cells/well in 6-well culture plates.
When cells reached 75% confluency, they were serum-
starved for 24 h in RPMI. Then, they were treated for
24 h in serum-free medium containing 50 μmol/L fatty
acid-free bovine serum albumin (BSA, Sigma Aldrich)
added with PC-DHA (30 μM) or AceDoPC (30 μM) in
0.1% ethanol or 0.1% ethanol used as vehicle. These
concentrations were chosen on the basis of optimal
biological effects of DHA previously reported [2]. In
addition, the solvent used (0.1% ethanol) has no effect
on cytokine production and cell viability [2, 16]. Where
specified, cells were further treated with 1 μg/mL LPS (E.
coli, 0127:B8, Sigma Aldrich, Lyon, France) for 3 or 6 h or
with 10 ng/mL interleukin-6 (IL-6, R&D Systems, Lille,
France) diluted in NaCl for 30, 60, or 90 min. BV-2 cells
treated with NaCl alone were used as control [2, 16].
Plasma cytokine assay
Cytokine assays were performed as previously described
[8]. The limit of detection was 1.1 pg/ml for IL-6,
2.3 pg/ml for TNFα, 5.4 pg/ml for IL-1β, 1.1 pg/mL for
IFNγ, and 2.0 pg/mL for IL-10. Briefly, samples diluted
1/2 were added to a 96-well microtiter plate (25 μL/well)
coated with beads (Millipore, France), covered with
aluminum foil, and incubated overnight on a shaker at
4 °C in the dark. After removal of sample using a mag-
net, beads were incubated with detection antibodies for
1 h at room temperature while shaking, followed by
streptavidin-PE for 30 min. The beads were then re-
suspended in 150 μL sheath fluid and analyzed using the
BioPlex 200 system (Bio-Rad, France). The reader was
set to read a minimum of 50 beads with an identical
fluorescence expressed as the median fluorescence in-
tensity. Median fluorescence intensity readings were
converted to pg/mL using calibration curves prepared
with cytokine standards included in the kit.
RT-PCR
Total RNA were extracted from brain structures and
BV-2 cells using Trizol (Invitrogen, Life Technologies).
RNA purity and concentration were determined using a
Nanodrop spectrophotometer (Nanodrop technologies,
Wilmington, DE). One microgram of RNA was reverse
transcribed to synthesize cDNA using Superscript III
and oligo random hexamers (Invitrogen, Life Technolo-
gies™, Saint-Aubin, France) [5]. Quantitative PCR was
then performed using the Applied Biosystems Assay-on-
Demand Gene Expression Products protocol (Foster
City, CA, USA), as previously described [6]. Briefly,
target cDNAs and reference cDNAs (β2-microglobulin)
were amplified by PCR using Taqman gene expression
assays for sequence-specific primers purchased from
Applied Biosystems (Foster city, CA, USA) [3, 5, 38].
We focused on the expression levels of IL-1β, IL-6, and
TNFα as pro-inflammatory markers. Reactions were
performed in duplicate according to manufacturer’s in-
structions as previously described [39]. PCR program
consisted of 40 cycles of 95 °C for 15 s and 60 °C for
1 min. Fluorescence was measured using an AB 7500
Real-Time PCR system (Applied Biosystems, Foster city,
CA), and final quantification was carried out using the
comparative threshold (Ct) method as previously de-
scribed [3, 6, 7, 40]. Results are expressed as relative fold
change to control target mRNA expression.
FACS analysis
BV-2 cells preparation was incubated with anti-CD16/
CD32 antibody (rat, eBiosciences, Paris, France) to block
Fc receptors for 5 min on ice. Cells were washed and
then incubated for 1 h with anti-gp80-PE (rat, Biolegend,
Ozyme, France) and anti-gp130-APC (rat, eBiosciences,
Paris, France). After washing, cells were then suspended
in PBS/BSA 0.1% for analysis. Non-specific binding was
assessed by using non-specific, isotype-matched anti-
bodies (PE-Rat IgG2b κ Isotype; APC-Rat IgG2a κ
Isotype, Biolegend). Antigen expression was determined
using a Becton–Dickinson LSR Fortessa™ multicolor cyt-
ometer (Franklin Lakes, NJ, USA). Ten thousand events
were recorded for each sample and isotype matched-
conjugate. Data were analyzed using FlowJo software
and gating for each antibody was determined based on
non-specific binding of appropriate negative isotype
stained controls [6].
Western blot analysis
After treatments, cells were washed twice in ice-cold
phosphate-buffered saline (PBS) 0.1%, scraped off, and
centrifuged at 1500 rpm for 10 min at 4 °C. For protein
extraction, cell pellets were homogenized in 100 μL of
lysis buffer (1 M TrisHCl pH 7.4, 0.5 M EDTA, 1 M
MgCl2, 1 M dithiothreitol, 1 M Na orthovanadate, 100
mMNaF, and protease cocktail inhibitor) on ice. After
incubation on ice for 30 min, samples were centrifugated
for 6 min at 6000 rpm at 4 °C. Protein concentration
was assessed by bicinchoninic acid assay (Interchim,
Montluçon, France), according to the manufacturer’s
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instructions. Equal amounts of protein (50 μg) were
loaded and separated on SDS-polyacrylamide gels (10%)
and transferred onto polyvinyl difluoride membranes
(Merck Millipore, Molsheim, France). Membranes were
saturated with a blocking solution containing 5% nonfat
dried milk and 0.05% Tween-20. Membranes were incu-
bated overnight at 4 °C in a solution containing 5% BSA
with the following primary antibodies: anti-phospho-
STAT3 (rabbit, Cell Signaling, 1:500), anti-STAT3 (rabbit,
Santa cruz, 1:1000), and anti-actin (rabbit, Biolegend,
1:2500). After washing, membranes were incubated for
1 h at room temperature with a rabbit peroxidase-
conjugated secondary antibody (1:5000, Jackson Immuno
Research Laboratories, Westgrove, PA, USA). The blots
were developed using Western Lighting Chemilumines-
cence Reagent Plus (PerkinElmer Life Science, Waltham,
MA, USA). Chemiluminescence was captured by a
Syngene detection system and quantified by Gene Tools
software (Syngene, Cambridge, UK). Between each
revelation, membranes were incubated for 15 min in
Re-Blot Plus Strong Antibody Stripping Solution
(Merck Millipore, Molsheim, France) according to
manufacturer’s instructions in order to remove the
previous antibody.
Lipid analyses
Total lipids from brain structures and BV-2 cell prepara-
tions were extracted according to the method of Folch
et al. [41] and fatty acids were transmethylated according
to the method of Morrison and Smith [42]. Fatty acid
methyl esters (FAMEs) were analyzed on a FOCUS GC
gas chromatograph (Thermo Electron Corporation)
equipped with a split injector and a flame ionization
detector. Separation of FAMEs was performed with a
Fig. 1 Effect of LPS (6 h, 500 μg/kg, i.p) on cytokine expression in the hypothalamus and hippocampus of mice injected with control plasma (NaCl n = 3;
LPS n = 3), PC-DHA (NaCl n = 5; LPS n = 6) or AceDoPC (NaCl n = 4; LPS n = 5). Values are expressed as means ± SEM. **p < 0.01 and ***p < 0.001
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BPX70-fused silica capillary column (60m length × 0.22mm
internal diameter, 0.25 μm film thickness; SGE, Courta-
boeuf, France). The hydrogen inlet pressure was 100 kPa.
The injector and detector temperatures were at 250 and
280 °C, respectively. The oven was at 150 °C, increased to
190 °C at a rate of 1.5 °C min − 1 with a 27-min hold, and
increased to 230 °C at a rate of 20 °C min − 1 and then left
at this temperature for 25 min. FAMEs were identified by
making a comparison with commercial standards. Fatty
acid composition is expressed as the percentage of total
fatty acids.
Statistical analyses
All data are expressed as means ± standard error of the
mean (SEM). Statistical significance between multiple
groups was analyzed by two-way ANOVA (treatment ×
LPS). When two-way ANOVA revealed a significant inter-
action, significant effects were analyzed by Fisher’s LSD
post hoc test. For all other measurements, experimental
groups were compared using a one-way ANOVA analysis
followed by Tukey’s multiple comparison test. All statis-
tical tests were performed using a critical probability of
p < 0.05.
Results
PC-DHA and AceDoPC attenuate LPS-induced IL-6 mRNA
expression in the hippocampus
To investigate the potential anti-inflammatory effect of
PC-DHA and AceDoPC, mice were injected i.v. with PC-
DHA or AceDoPC 24 h prior to i.p. LPS administration.
LPS is known to induce pro-inflammatory cytokine ex-
pression in several brain structures, including the hippo-
campus and in the hypothalamus [43]. Pro-inflammatory
cytokine mRNA expression was measured by RT-qPCR in
these two brain structures 6 h after LPS injection (Fig. 1).
LPS increased mRNA expression of IL-1β, TNFα, and IL-
Fig. 2 Effect of LPS (6 h, 500 μg/kg, i.p) on cytokine and corticosterone concentration in the plasma of mice injected with control plasma (NaCl n = 3;
LPS n = 3), PC-DHA (NaCl n = 5; LPS n = 5) or AceDoPC (NaCl n = 5; LPS n = 4). Values are expressed as means ± SEM. *p < 0.05 and **p < 0.01
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6 in both the hypothalamus and the hippocampus of the
mice (hypothalamus: LPS effect IL-1β F(1, 18) = 110.6,
p < 0.001; TNFα F(1, 18) = 47.30, p < 0.001; IL-6 F(1,
18) = 18.57, p < 0.001; hippocampus: LPS effect IL-1β F(1,
22) = 45.25, p < 0.001; TNFα F(1, 22) = 81.99, p < 0.001).
The 2-way ANOVA analysis revealed a significant
treatment × LPS interaction (F(2, 22) = 5405 p < 0.05).
Post-hoc analysis further revealed a significant effect of
PC-DHA (p < 0.001) and of AcedoPC (p < 0.01) on LPS-
induced IL-6 mRNA expression.
PC-DHA and AceDoPC effects on IL-6 mRNA expression in
the hippocampus are not associated with changes in
plasma IL-6 concentration
To evaluate if PC-DHA and AceDoPC have an effect on
peripheral inflammatory response, we then measured the
concentration of pro- and anti-inflammatory cytokines in
the plasma of mice 6 h after LPS injection (Fig. 2). LPS in-
duced a significant increase in pro-inflammatory and anti-
inflammatory cytokine concentration (LPS effect: TNFα
F(1, 20) = 85.81, p < 0.001; IL-6 F(1, 18) = 31.33, p < 0.001;
IFNγ F(1, 20) = 24.68, p < 0.001; IL-10 F(1, 19) = 260.1,
p < 0.001) along with an increase in plasma corticosterone
levels (LPS effect, F(1, 19) = 213.0, p < 0.001). No significant
effect of PC-DHA and AceDoPC was observed for TNFα,
IL-6, IL-10, IFNγ, and corticosterone levels. Only LPS-
induced IL-1β was significantly reduced in mice injected
with PC-DHA or AceDoPC in comparison with vehicle-
treated mice (interaction treatment × LPS, F(2, 19) = 4.810,
p < 0.05). Hence, PC-DHA and AceDoPC effect on IL-6
mRNA levels in the hippocampus was not associated with
an effect on IL-6 levels at the periphery.
Fig. 3 Effect of LPS (6 h, 500 μg/kg, i.p) treatment on fatty acid composition in the hippocampus of mice injected with control plasma (NaCl
n = 3; LPS n = 3), PC-DHA (NaCl n = 5; LPS n = 6) or Acedo-PC (NaCl n = 5; LPS n = 6). Values are expressed as means ± SEM. C20:4 n-6:
arachidonic acid; C22:6 n-3: docosahexaenoic acid
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PC-DHA and AceDoPC effects in the hippocampus are not
associated to fatty acid composition changes
Fatty acids are known to modulate inflammatory re-
sponse in the brain, especially in the hippocampus;
therefore, we assessed the fatty acid content in this
brain structure (Fig. 3). Both PC-DHA and AceDoPC
treatments did not change the fatty acid composition
in the hippocampus. Moreover, our data showed that
6 h LPS did not alter either the fatty acid compos-
ition of this brain structure. Hence, PC-DHA and
AceDoPC effects on brain inflammatory response to
LPS were not due to changes in hippocampus fatty
acid composition.
Both PC-DHA and AceDoPC attenuate LPS-induced IL-6
mRNA expression in BV-2 cells
Because PC-DHA and AceDoPC effects in the hippo-
campus could be due to a direct effect on microglia,
the immune cells of the brain, we then assessed their
anti-inflammatory effect in vitro, in BV-2 cells. Cells
were incubated for 24 h with PC-DHA, AceDoPC, or
their control vehicle. LPS-stimulation (3 and 6 h) in-
duced an increase in IL-1β, TNFα, and IL-6 mRNA ex-
pression in comparison to NaCl in vehicle-treated cells
(Fig. 4). PC-DHA decreased LPS-induced IL-6 mRNA
expression 3 and 6 h after stimulation (interaction
treatment × LPS: 3 h F(2, 12) = 12.25, p < 0.01; 6 h F(2,
12) = 36.88, p < 0.001). Moreover, AceDoPC decreased
IL-6 mRNA expression 6 h after LPS stimulation in
comparison with vehicle group. These effects were spe-
cific to IL-6. Indeed, we did not observe any effect of
treatments on LPS-induced TNFα mRNA expression
and only an effect of PC-DHA on IL-1β mRNA expres-
sion 3 and 6 h after LPS stimulation (interaction
treatment × LPS: 3 h F(2, 12) = 10.70, p < 0.01; 6 h F(2,
12) = 8.75, p < 0.01).
Fig. 4 Cytokine expression in BV-2 cells treated with control vehicle, PC-DHA or AceDoPC for 24 h and stimulated with NaCl or LPS for 3 or 6 h.
Values are expressed as means ± SEM (n = 3). **p < 0.01 and ***p < 0.001
Fourrier et al. Journal of Neuroinflammation  (2017) 14:170 Page 7 of 13
AceDoPC decreases IL-6 receptor subunits surface
expression in microglial cells
We then investigated by flow cytometry analysis whether
PC-DHA and AceDoPC exerted their effects on IL-6
expression in BV-2 cells via the IL-6 receptor. We evalu-
ated the BV-2 cell surface expression of gp80 and gp130,
two subunits of the IL-6 receptor, after 24 h lipid
treatment and 0, 30, 60, or 90 min stimulation with IL-6
(Fig. 5). Lipid treatment and IL-6 did not change the
expression of gp80 subunit. However, gp130 expression
decreased after AceDoPC treatment (treatment effect:
30 min F = 4.072, p < 0.05; 60 min F = 5.369, p < 0.05;
90 min F = 17.46, p < 0.001). PC-DHA decreased gp130
expression only 90 min after LPS treatment (treatment
effect: 90 min F = 2.140, p < 0.01).
AceDoPC decreases IL-6-induced STAT3 activation
Due to the effect of AceDoPC on IL-6 receptor subunit
expression, we then assessed if the activation of the pro-
inflammatory signaling pathway associated with the IL-6
receptor, the STAT3 pathway, was different under IL-6
stimulation (Fig. 6). When the cells were treated with Ace-
DoPC, 30-min IL-6 treatment decreased STAT3 phosphor-
ylation in comparison to vehicle- and PC-DHA-treated
microglial cells (treatment effect: F = 3.850, p < 0.05).
These results suggest that AceDoPC not only had an effect
on IL-6 expression but also on its receptor and its associ-
ated signaling pathway.
BV-2 fatty acid composition
Finally, to test whether PC-DHA and AceDoPC affect
the fatty acid composition of BV-2 cells, fatty acid
contents were assessed by gas chromatography. Table 1
shows that both treatments induced a significant in-
crease in n-3 PUFAs (treatment effect: F = 379.6,
p < 0.001), and specifically in DHA (22:6 n-3) (treatment
effect: F = 542.8, p < 0.001), inducing a decrease in n-6/
n-3 ratio (treatment effect: F = 118.2, p < 0.001). More-
over, data showed that AceDoPC treatment significantly
decreased the amount of saturated fatty acids in the
membrane of BV-2 cells in comparison with vehicle-
treated cells (treatment effect: F = 5.218, p < 0.05).
Discussion
In this work, we found that in vivo, a single injection of
AceDoPC or PC-DHA decreases LPS-induced IL-6 pro-
duction in the hippocampus of mice. To further understand
whether the effect of these molecules was due to their ac-
tivity on microglia, we tested their activity in vitro. Our re-
sults revealed that both AceDoPC and PC-DHA were able
to decrease LPS-induced IL-6 expression, while PC-DHA
had also an effect on IL-1β. In addition, these molecules
reduced IL-6 receptor surface expression while only Ace-
DoPC decreased IL-6-induced STAT3 phosphorylation.
Altogether, these results highlight the potency of AceDoPC
to regulate IL-6 production and signaling in microglia.
In the last decade, DHA has been recognized as a mol-
ecule with anti-inflammatory activity in the brain [1, 44].
This activity is thought to be linked to its direct [14] or
indirect [16] effect on microglia, thereby opening strat-
egies for their use in several brain diseases with an
inflammatory component [45]. In rodents, brain DHA in-
crease through dietary, genetically or pharmacologically
means protects from neuroinflammation linked to aging
[5], pro-inflammatory treatment [3, 14, 46], or acute injury
[47–49]. Importantly, the acute increase of DHA in the
hippocampus of mice is sufficient to attenuate neuroin-
flammatory processes triggered by the i.c.v. administration
of LPS [4, 9]. Conversely, rodent studies with n-3 PUFA
dietary deficiencies leading to decreased DHA brain levels
result in increased inflammatory cytokine expression, in
particular IL-6 in the brain [7, 8, 50]. In humans, lower
levels of blood DHA were associated to higher IL-6 levels
and depression/anxiety scores after an interferon treat-
ment or in healthy young adults [51–53]. Interestingly,
EPA and DHA supplementation reduce inflammatory
markers in depressed subjects [54]. However, whether a
single, acute administration of DHA controls neuroin-
flammation has not been evaluated. Repeated intraperito-
neal administration of DHA decreases neuroinflammatory
Fig. 5 IL-6 receptor subunit protein expression in BV-2 cells treated with
control vehicle, PC-DHA or AceDoPC for 24 h and stimulated with IL-6 for
0, 30, 60, and 90 min. Values are expressed as means ± SEM. *p < 0.05,
**p < 0.01, and ***p < 0.001 when compared to its respective control
group; #p < 0.05 when compared to its respective PC-DHA group
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pathways activated by traumatic brain injury in rats [55].
Recent work reports that intravenous administration of
unesterified DHA induces a transient increase in plasma
DHA [56] with a rapid brain uptake [26]. Importantly,
DHA, when consumed as phospholipid (PL) forms, en-
ters the brain more effectively than as triglyceride
forms [4, 57]. In addition, if the plasma non-esterified
DHA is sufficient to replace the brain DHA pool, the lon-
ger half-life of lysoPC-DHA allows for a longer brain ex-
posure to DHA [26]. This is in line with the discovery of
the presence of MFSD2A at the BBB, a specific trans-
porter of DHA in the lysoPC form [33]. We tested the ef-
fect of AceDoPC that mimics lysoPC [34] on LPS brain
inflammatory response and compared it to PC-DHA. In
vivo, both forms decreased LPS-induced IL-6 production
in the hippocampus, but not in the hypothalamus. This
suggests that these molecules equally targeted the hippo-
campus. However, this could be independent of their brain
accumulation, as we could not detect any increase of
DHA in the hippocampus (Fig. 3). This is in line with the
work of Bazinet’s group, who elegantly demonstrated that
the unesterified DHA pool, but not the total phospholipid
DHA, is critical to regulate i.c.v. LPS-induced cytokine
production in the hippocampus [4, 9]. However, as DHA
was only measured in the whole hippocampus, we cannot
rule out that DHA accumulates in specific substructures
such as the BBB or a specific cell type, such as microglia.
Further studies are warranted to elucidate this point. The
long lasting effect of AceDoPC and PC-DHA 6 h after
LPS administration could be linked to their longer half-life
in the plasma and in the brain [26].
We cannot exclude that the anti-inflammatory effect
of administered forms of DHA on hippocampal IL-6 is
due to their peripheral effect. Indeed, both molecules de-
creased IL-1β in the plasma of LPS-treated mice, which
could influence IL-6 brain level as IL-1β has been shown
to be the main cytokine activating IL-6 production in
the brain [58]. Of note, crawling monocytes are detected
in cerebral vasculature of LPS-treated mice [37] and
could be directly targeted by AceDoPC and PC-DHA
before entering the brain, therefore producing less cyto-
kine. However, monocyte entry is dependent on TNFα
[20, 37] that is not downregulated by AceDoPC or PC-
DHA. As only hippocampal, and not hypothalamic IL-6
expression is affected by DHA, together with the fact
that the hippocampus is more sensitive to DHA vari-
ation [19], we speculate that DHA targets this structure.
This direct effect of esterified form of DHA is consistent
with previous studies showing that a single injection of
DHA reduces microglia activation after spinal cord
Fig. 6 STAT3 protein expression and activation in BV-2 cells treated with control vehicle, PC-DHA or AceDoPC for 24 h and stimulated with IL-6
for 0, 30, 60, and 90 min. Values are expressed as means ± SEM. *p < 0.05 when compared to its respective control group; #p < 0.05 when
compared to its respective PC-DHA group
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injury [59, 60] or stroke [13, 61]. However, additional in
vivo experiments are warranted to determine whether
AceDoPC and PC-DHA enter the hippocampus and tar-
get microglia to reduce IL-6 production in the context
of LPS administration. In addition, according to our in
vitro data showing that both IL-6 production and IL-6
signaling are downregulated by AceDoPC and PC-DHA,
the analysis of their effect on IL-6 signaling in the hippo-
campus is of interest for future studies.
To assess whether AceDoPC and PC-DHA target
microglia, which are the main cells producing pro-
inflammatory cytokines in the brain in response to
Table 1 Fatty acid composition of BV-2 cells treated with control vehicle, PC-DHA, or AceDoPC for 24 h. Values are expressed as
means ± SEM (n = 4)
Control n = 4 PC-DHA n = 4 Acedo-PC n = 4 p value
mg/100 mg fatty acids
c12:0 3.1 ± 0.30 1.6 ± 0.79* 1.3 ± 0.54* 0.01
c14:0 7.1 ± 0.23 5.4 ± 1.48 4.4 ± 1.27* 0.05
c15:0 0.4 ± 0.03 0.4 ± 0.01 0.4 ± 0.02 0.46
c16:0 23.9 ± 0.82 21.1 ± 1.83 21.5 ± 1.17 0.07
c17:0 0.3 ± 0.01 0.3 ± 0.01 0.2 ± 0.01 0.54
c18:0 9.3 ± 0.20 9.8 ± 0.43 10.5 ± 0.82 0.07
c20:0 0.5 ± 0.30 0.2 ± 0.01 0.2 ± 0.02* 0.04
c22:0 0.3 ± 0.04 0.3 ± 0.06 0.3 ± 0.02 0.13
c24:0 0.9 ± 0.04 1.0 ± 0.09 0.9 ± 0.04 0.25
Saturated 45.6 ± 0.74 40.0 ± 3.56 39.7 ± 2.36* 0.04
c16:1n-9 3.0 ± 0.07 3.4 ± 0.22* 3.2 ± 0.15 0.04
c16:1n-7 2.5 ± 0.07 2.6 ± 0.12 2.7 ± 0.10 0.08
c18:1 t 2.1 ± 0.36 0.8 ± 0.24*** 0.6 ± 0.04*** < 0.0001
c18:1 n-9 22.3 ± 0.56 23.0 ± 1.40 23.5 ± 0.84 0.40
c18:1 n-7 8.2 ± 0.14 9.1 ± 0.44* 9.4 ± 0.44** 0.01
c20:1 n-9 0.6 ± 0.01 0.6 ± 0.07 0.6 ± 0.05 0.71
c24:1 n-9 1.3 ± 0.03 1.5 ± 0.11a* 1.6 ± 0.10* 0.01
Monounsaturated 40.0 ± 0.80 41.0 ± 2.16 41.5 ± 1.53 0.52
c18:2 n-6 0.3 ± 0.02 0.3 ± 0.03 0.3 ± 0.04 0.92
c20:4 n-6 1.4 ± 0.08 1.4 ± 0.10 1.4 ± 0.09 0.86
c22:4 n-6 0.2 ± 0.03 0.1 ± 0.02 0.1 ± 0.01 0.08
c22:5 n-6 0.1 ± 0.02 0.1 ± 0.01 0.1 ± 0.01 0.07
n-6 2.0 ± 0.10 1.9 ± 0.10 1.9 ± 0.11 0.64
c18:3 n-3 0.2 ± 0.01 0.2 ± 0.01 0.2 ± 0.02 0.26
c22:5 n-3 0.3 ± 0.12 0.4 ± 0.22 0.4 ± 0.02 0.43
c22:6 n-3 0.6 ± 0.08 3.7 ± 0.19*** 3.9 ± 0.11*** < 0.0001
n-3 1.1 ± 0.19 4.3 ± 0.21*** 4.6 ± 0.13*** < 0.0001
c20:3 n-9 5.9 ± 0.07 6.3 ± 0.68 5.8 ± 0.44 0.34
Polyunsaturated 9.0 ± 0.32 12.5 ± 0.95*** 12.3 ± 0.61*** < 0.0001
dma16:0 1.9 ± 0.03 2.5 ± 0.15** 2.5 ± 0.13*** < 0.0001
dma18:0 0.9 ± 0.03 1.0 ± 0.12 1.1 ± 0.10 0.13
dma18:1 n-9 1.4 ± 0.03 1.6 ± 0.13 1.5 ± 0.06 0.07
dma18:1 n-7 1.2 ± 0.02 1.4 ± 0.08* 1.4 ± 0.08 0.02
DMA 5.4 ± 0.10 6.5 ± 0.48* 6.5 ± 0.35* 0.01
n-6/n-3 1.8 ± 0.26 0.4 ± 0.01*** 0.4 ± 0.01*** < 0.0001
*p < 0.05, **p < 0.01, and ***p < 0.001 for comparison with control
DMA dimethylacetals, PC phosphatidylcholine
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inflammatory stimuli, we assessed these cells in in vitro
studies. Both molecules reduced LPS-induced IL-6
expression in microglia, with PC-DHA also reducing IL-
1β. Of note, while DHA downregulated LPS-induced IL-
1β mRNA expression in vitro, it was not the case in vivo.
Our previous work showed that DHA downregulated
LPS-induced IL-1β release at high (30 μM) but not low
concentration (0.3 and 3 μM) [2], suggesting that a cer-
tain amount of DHA is required to regulate LPS-
induced IL-1β synthesis and release in microglia. Here,
we used ≈ 60 μM of DHA in vivo and 30 μM of DHA in
vitro. In vitro, such dose is sufficient to increase DHA
levels in microglia (Table 1). Whether the 60 μM of
DHA is sufficient to target microglia and IL-1β produc-
tion in vivo remains to be demonstrated.
To our knowledge, this is the first study to test the
anti-inflammatory activity of DHA esterified on phos-
pholipids in microglia. Free DHA has been previously
reported to reduce LPS-induced IL-1β, IL-6, and TNFα
through its effect on LPS receptors and signaling path-
way [2]. Other mechanisms such as antioxidant activity
[62] or lipid bodies and organelle reorganization [63, 64]
have been demonstrated to mediate the anti-inflammatory
activity of unesterified DHA. In this study, we identify an
additional effect of AceDoPC on IL-6 receptors and
STAT3 phosphorylation, which is a hallmark of IL-6 sig-
naling pathway activation. IL-6-induced-STAT3 in the
brain has been reported to be important in mediating the
behavioral effect of LPS [7]. In addition, this pathway is
regulated in vivo by DHA content in the brain [7]. DHA
inhibitory effect on IL-6 activity has been previously re-
ported in hepatocytes and osteoblasts, with a very specific
effect [65, 66]. Of note, DHA inhibitory effect on STAT3
phosphorylation has been previously reported to involve
PPARγ [65, 67]. In human gastric epithelial cells, DHA in-
creased the mRNA level of SOCS3, a negative regulator of
STAT3 signaling [25, 67]. Interestingly, bacteria-induced
STAT3 activation is reduced by DHA through a specific
PPARγ-SOCS3 (a negative regulator of STAT3 signaling)
[25, 67]. Whether this is the case in microglia in vitro and
in vivo remains to be evaluated.
Previous work suggests that COX-2 upregulates IL-6
associated STAT3 signaling [68]. In an in vitro assay,
AceDoPC reduces COX-2 activity (data not shown). In
line with this, previous work conducted in macrophages
revealed that DHEA, a DHA-derivative ethanolamide,
downregulates COX-2 expression [26, 69]. However,
whether AceDoPC’s specific effect (direct or through de-
rivatives) on the IL-6 signaling pathway involves COX-2
remains to be tested. An additional mechanism under-
lying AceDoPC’s effects on IL-6 induced-STAT3 phosphor-
ylation could be linked to the decreased expression of
gp130, the co-receptor of IL-6. Recent studies highlight that
gp130/STAT3 phosphorylation is involved in the pro-
inflammatory activity of IL-6, while gp130 mediates IL-6 ef-
fect on tissue repair and recovery after infection [70]. Fur-
ther studies are warranted to determine whether AceDoPC
decreases brain IL-6 activity through its effect on gp130 in
vivo.
Conclusions
These results show that AcedoPC modulates LPS-induced
neuroinflammation and IL-6 signaling in microglia. As
AcedoPC is a specific carrier of DHA and may increase its
brain penetration, it represents a therapeutic application
for treating neuroinflammation.
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